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Summary 
Venous thromboembolism (VTE), including deep vein thrombosis (DVT) and pulmonary 
embolism (PE), is a prevalent and potentially fatal cardiovascular disease (CVD). VTE and 
arterial CVD (i.e. myocardial infarction (MI) and ischemic stroke) have been considered as 
separate diseases. However, recent studies have proposed an association between VTE and 
arterial CVD. The aim of the thesis was to investigate this association in a general population. 
 Papers I-III are prospective cohorts with participants from general populations (i.e. the 
Tromsø Study (papers I-III) and the Diet, Cancer and Health Study (paper II)). Paper IV is a 
matched cohort with participants attending ≥ 2 carotid ultrasounds in the Tromsø Study. 
 Incident MI was associated with a transient increase in VTE risk, and a particularly 
high risk was found for PE during the first 6 months after MI. MI explained 6% of the PE 
events in the population. Incident VTE was associated with increased risk of future arterial 
CVD independent of atherosclerotic risk factors in all women and men < 65 years of age, and 
explained 1% of the arterial thrombotic events in the population. The risk of arterial CVD was 
particularly high the first year after a PE. Family history of MI (FHMI) was a risk factor for 
both MI and VTE in a cause-specific and a traditional Cox model. The association between 
FHMI and VTE applied to unprovoked DVT and was neither explained by atherosclerotic risk 
factors nor MI as an intermediate event. We found that incident VTE was associated with 
plaque progression in subjects with carotid plaques, but not with novel carotid plaque 
formation. The possible association between VTE and carotid plaque progression was not 
mediated by chronic inflammation secondary to the VTE.  
Based on our findings, there appears to be a bidirectional and transient association 
between VTE and arterial CVD. Family history of MI is a shared risk factor for VTE and MI, 
and atherosclerosis may partly mediate the association between VTE and future arterial CVD.  
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Sammendrag 
Venøs tromboembolisme (VTE) inkluderer dyp venetrombose (DVT) og lungeemboli (LE) og 
er en hyppig og potensielt dødelig kardiovaskulær sykdom (KVS). VTE og arteriell KVS 
(hjerteinfarkt og slag) ble tidligere ansett for å være separate sykdommer. Nyere studier har 
imidlertid antydet en mulig sammenheng mellom VTE og arteriell KVS. Målet med denne 
avhandlingen var å undersøke sammenhengen mellom VTE og arteriell KVS i en generell 
befolkning.  
 Artikkel I-III er prospektive kohorter med deltakere fra generelle befolkninger 
(Tromsøundersøkelsen (artikkel I-III) og Diet, Cancer and Health-studien (artikkel II)). 
Artikkel IV er en kohort av de med ≥2 karotisultralydmålinger i Tromsøundersøkelsen. 
  Førstegangs hjerteinfarkt var assosiert med en forbigående økt risiko for VTE, og 
risikoen var spesielt høy for LE de første 6 månedene etter hjerteinfarkt. Hjerteinfarkt 
forklarte 6% av LE-hendelsene i populasjonen. Førstegangs VTE økte risikoen for fremtidig 
arteriell KVS uavhengig av aterosklerotiske risikofaktorer blant alle kvinner og menn <65 år, 
spesielt det første året etter LE, og forklarte 1% av tilfellene med arteriell KVS i 
populasjonen. Familiehistorie av hjerteinfarkt var en risikofaktor for både hjerteinfarkt og 
VTE, både i en årsaks-spesifikk og en tradisjonell Cox-modell. Sammenhengen mellom 
familiehistorie av hjerteinfarkt og VTE gjaldt uprovosert DVT og kunne ikke forklares av 
aterosklerotiske risikofaktorer eller hjerteinfarkt. Førstegangs VTE var forbundet med økt 
progresjon, men ikke nydannelse av åreforkalkning på halspulsåren. Den mulige 
sammenhengen mellom VTE og åreforkalkning var ikke mediert av lavgradig inflammasjon.  
 Basert på våre funn synes det å være en toveis og forbigående sammenheng mellom 
VTE og arteriell KVS. Familiehistorie av hjerteinfarkt er en felles risikofaktor for VTE og 
hjerteinfarkt, og åreforkalkning kan mediere sammenhengen mellom VTE og arteriell KVS.  
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1. Introduction 
Venous thromboembolism (VTE) is a collective term for deep vein thrombosis (DVT) and 
pulmonary embolism (PE), and has been acknowledged as the 3rd leading cause of 
cardiovascular death in Western countries, following myocardial infarction (MI) and ischemic 
stroke.1 Although the clinical manifestations of VTE are diverse, pain, edema and erythema 
are prevalent symptoms and signs of DVT, and dyspnea, tachypnea and chest pain are 
frequent PE symptoms.2 Previously, initial treatment with parenteral anticoagulants (e.g. low-
molecular-weight heparin (LMWH)) and subsequent long-term treatment with vitamin K 
antagonists (VKAs, e.g. warfarin) was recommended for VTE patients without cancer, and 
LMWH was recommended as treatment for VTE patients with cancer.3 Growing evidence 
supports that direct oral anticoagulants (DOACs), including direct thrombin inhibitors (e.g. 
dabigatran) and factor (F) Xa inhibitors (e.g. rivaroxaban and apixaban), have similar efficacy 
on VTE recurrence but reduced risk of bleedings when compared with warfarin for the long-
term treatment of VTE.4-7 In the present American College of Chest Physicians (ACCP) 
guidelines, DOACs are suggested over VKAs in the long-term treatment of VTE in patients 
without cancer.8 
 
1.1 Epidemiology of venous thromboembolism  
VTE is a frequent disease with an overall incidence rate ranging from 1 to 2 per 1000 in 
general populations.9-14 The incidence of DVT is higher than the incidence of PE,9-11 and the 
VTE incidence has consistently been shown to increase exponentially with advancing age.9-11, 
13, 14 Moreover, the VTE incidence has been found to vary according to ethnicity, with the 
highest incidence demonstrated in subjects of African-American origin, followed by subjects 
of Caucasian and then Hispanic and Asian origin.12, 15 A significant increase in the incidence 
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of VTE has been reported during the last decades, regardless of improvements in VTE 
prophylaxis, diagnostics and treatment.10, 16 Over-diagnosis due to increasing use of 
noninvasive diagnostic procedures such as computer tomography (CT) is suggested to partly 
explain this observed increase in VTE incidence. In agreement with this, the incidence but not 
the mortality of PE was found to increase after the introduction of CT.17 
VTE has been shown to recur in 6 to 13% of VTE patients the initial year after the 
incident VTE diagnosis,11, 13, 18 and in up to 30% within 10 years.13, 18, 19 The highest risk of 
recurrence has been found during the initial 6 to 12 months after the incident VTE.13, 18, 20 A 
particularly high risk of recurrence has also been reported in VTE patients with PE,21 an 
unprovoked event,22, 23 cancer,20, 22 or high age.11 Moreover, a tendency for VTE to recur at 
the same location as the initial event (i.e. DVT or PE) has been shown.24 The post-thrombotic 
syndrome, including chronic pain, heaviness, venous stasis, skin changes and venous ulcers in 
the lower extremity, is the most common complication of DVT, and occurs in 20 to 50% of 
DVT patients.13, 19, 22, 25 Specifically, patients with proximal DVT,22, 26 high body mass index 
(BMI) or high age22 have been found to have particularly high risk of the post-thrombotic 
syndrome. Pulmonary hypertension is a serious complication of PE resulting in elevated 
pulmonary artery pressure and persistent dyspnea, and occurs in 1 to 4% of PE patients.23, 27-29 
VTE is also associated with increased risk of death, and up to 14%9, 11, 30 and 30%9, 19, 
30 of VTE patients are reported to die the initial month and year after the VTE diagnosis, 
respectively. The highest risk of death has been demonstrated the initial time-period after the 
VTE diagnosis.9, 31 A high risk of death has also been found in VTE patients with PE9, 13, 15, 24 
and cancer.9, 11, 20, 32 Cancer has been identified as the strongest risk factor for all-cause 
mortality in VTE patients,11, 32, 33 and PE was the cause or contributing cause of death in a 
considerable number of hospitalized patients, most of which died within 2.5 hours following 
the PE.34 
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1.2 Pathophysiology of venous thromboembolism 
Autopsy and radiology studies have shown that venous thrombi originate near the vessel wall 
in the apex of venous valve pockets.35, 36 In contrast to arterial thrombi, which are preceded by 
endothelial damage and are rich in platelets, venous thrombi may form independently from 
endothelial damage and mainly contain red blood cells and fibrin.35 According to Virchow’s 
triad, the development of venous thrombi results from hypercoagulable changes of the blood 
composition, alterations of the vessel wall and blood stasis (Figure 1).37 
 
Figure 1. Virchow’s triad. Venous thrombus formation results from hypercoagulability, 
alterations of the vessel wall (e.g. vessel wall injury) and blood stasis. 
 
Stasis frequently occurs in venous valve pockets,38 and traps the blood in a secondary 
vortex and triggers hypoxia.39, 40 Hypoxia in turn modulates the endothelial cells in the venous 
valve pocket to express adhesion molecules, release chemo attractants and alter the balance of 
anti- and pro-coagulant proteins.40-44 This results in binding of circulating leukocytes (e.g. 
monocytes), platelets and extracellular vesicles (Figure 2).40, 45, 46 Hypoxia may also activate 
leukocytes to release extracellular vesicles (Figure 2).47 Extracellular vesicles are highly pro-
coagulant because of presence of tissue factor (TF) and exposure of negatively charged 
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phospholipids such as phosphatidyl serine on the surface.48, 49 TF may initiate the coagulation 
cascade by binding to FVII/VIIa and the TF-FVIIa complex, and phosphatidyl serine 
facilitates assembly of coagulation factors.50 
 
Figure 2. The pathophysiology of venous thromboembolism. The blood is trapped in the 
venous valve pockets, and subsequent hypoxia promotes a pro-coagulant response in the 
endothelial cells of the valve pocket and activates blood cells (e.g. platelets (Plt) and 
monocytes (Mc)). This results in binding of leukocytes, platelets and micro particles (MP, i.e. 
extracellular vesicles) at the endothelial surface, and release of pro-coagulant extracellular 
vesicles from the activated blood cells. 
 
Results of emerging studies indicate that venous thrombi originate in deep calf 
veins,51, 52 and gradually grow proximally53 and become symptomatic due to vessel 
obstruction and impaired venous return.53, 54 However, thrombi solely in the ilio-femoral veins 
were found in some DVT patients,36, 52 indicating that venous thrombi may originate in more 
proximal veins than calf veins. Thrombi may break free from the lower extremity veins and 
cause PE if they pass through the right side of the heart, reach the lungs and obstruct a 
pulmonary artery (Figure 3). In accordance with this, half of the venous thrombi in DVT 
patients were non-adherent to the vessel wall,52 and evidence of PE has been demonstrated in 
nearly 40% of DVT patients without PE symptoms.55 Moreover, the risk of PE has been 
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shown to increase with increasing proximity of the DVT to the pelvis.56-58 Conversely, other 
studies have shown that only 40 to 60% of PE patients had a concurring leg thrombus,57, 59, 60 
and that PE without DVT was particularly prevalent after trauma60 and occurred secondary to 
atrial fibrillation (AF) in 15%.61 This suggests that PE may arise independently from DVT. 
 
Figure 3. The pathophysiology of deep vein thrombosis (DVT) and pulmonary embolism 
(PE). Venous thrombus formation takes place in valve pockets of deep veins in the lower 
extremities. Parts of a venous leg thrombus may break free, follow the blood through the right 
side of the heart and obstruct a pulmonary artery, resulting in PE. 
 
1.3 Risk factors for venous thromboembolism 
VTE is a complex disease associated with multiple hereditary and acquired factors (i.e. risk 
factors). Even if several risk factors for VTE have been identified, 25 to 50% of VTE events 
in a general population were unprovoked and not attributed to presently known risk factors for 
VTE.11, 62 In most VTE patients, a combination of several underlying risk factors has been 
found.11, 62 Moreover, the risk of VTE has been shown to change according to age.9, 11, 13, 14 
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Therefore, a dynamic and age-dependent VTE risk model has been proposed.63 In this model, 
risk factors interact and venous thrombi form when the combination of risk factors yield a 
thrombosis potential exceeding the thrombosis threshold of a subject (Figure 4).63  
 
Figure 4. The thrombosis potential model. The blue line represents a hereditary risk factor for 
VTE (e.g. Factor V Leiden), and the red line represents increasing age. The green line 
represents the combined effect of the hereditary factor, age and provoking factors (e.g. 
trauma, surgery or use of oral contraceptives) on the thrombosis potential at different time 
points. The former combination of risk factors is not sufficient to cause VTE, whereas in the 
latter situation, the thrombosis potential exceeds the thrombosis threshold. 
 
1.3.1 Hereditary risk factors 
Family-based and twin studies have shown that VTE has a strong genetic risk component and 
an estimated heritability of 50 to 60%.64-66 The first genetic risk factor discovered for VTE 
was antithrombin deficiency, which is caused by mutations in the SERPINC1 gene. 
Antithrombin deficiency is present in approximately 0.02% of the population67, 68 and has 
been found to increase the risk of VTE 10-fold.67 Shortly after the discovery of antithrombin 
deficiency, non-O blood groups were identified as a genetic risk factor for VTE.67 Non-O 
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blood groups are highly prevalent and were present in 70% of VTE patients and 54% of 
healthy controls in a large meta-analysis.69 Non-O blood groups have been shown to increase 
the risk of VTE by 1.5 to 2-fold compared with the O blood group,67, 70-73 and the risk of VTE 
associated with non-O blood groups was particularly high for unprovoked events70 and in 
subjects with thrombophilia (e.g. FV Leiden or prothrombin 20210A carriers).70, 72, 74 Non-O 
blood groups are believed to mediate VTE risk through elevated levels of von Willebrand 
Factor (vWF) and FVIII,71 which are demonstrated to have a positive dose-response 
relationship with VTE occurrence.75, 76 In agreement with this, genetic loci associated with 
plasma levels of vWF and FVIII have been identified as risk factors for VTE.77, 78 However, 
non-O blood groups remained significantly associated with VTE after taking vWF and FVIII 
levels into consideration in some studies,73, 79 which implies that non-O blood groups may 
mediate VTE risk through other mechanisms than elevated vWF and FVIII levels. 
 Protein C and S deficiencies have later been identified as risk factors for VTE, and are 
caused by gene mutations present in 0.03 to 0.2% of the population.67, 80 Activated protein C 
(APC) limits clot formation by inactivating FV and FVIII,67 and low levels or deficiency of 
protein C have been found to increase the risk of VTE 3 to 7 times.79, 81, 82 Protein S is a 
cofactor to APC, and both low and deficient protein S have been demonstrated to increase the 
risk of VTE.83-85 FV Leiden is a mutation in the factor V gene resulting in hypercoagulability 
due to reduced ability of FV to be inactivated by APC.86, 87 FV Leiden has a frequency of 
approximately 5% in the European population,67, 87 and has been found to increase the risk of 
VTE 3 to 5-fold.67, 69, 88, 89 The highest risk of VTE associated with FV Leiden has been found 
for DVT compared with PE.69, 89, 90 A particularly high risk of VTE has also been shown in 
homozygous or young FV Leiden carriers.89 Furthermore, FV Leiden has been demonstrated 
to have a synergistic effect with oral contraceptives,89, 90 pregnancy,91 smoking,92 obesity92, 93 
and the prothrombin 20210A mutation89, 90 on the risk of VTE. 
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The discovery of FV Leiden was followed by the identification of prothrombin 
20210A as a potential risk factor for VTE.67 Prothrombin 20210A is a prothrombin mutation 
found to significantly increase the plasma prothrombin level.94 The prothrombin 20210A 
mutation has a reported prevalence of 2% in the population,67, 95 and has been shown to 
increase the risk of VTE 3-fold.67, 89, 94 Furthermore, prothrombin 20210A has been found to 
have a stronger effect on VTE risk in women commencing oral contraceptives,89, 90 pregnant 
women,91 heavy smokers92, 93 and obese.92 In contrast, other studies have reported that 
prothrombin 20210A did not significantly increase the risk of VTE after taking factors such as 
age, sex, BMI, smoking and oral contraceptive use into account,96 and that prothrombin 
20210A was not associated with VTE in the elderly.97 
 During the last two decades, technological advances have made it possible to detect 
new genetic risk factors for VTE,67, 88 and 12 genes harboring novel risk alleles for VTE have 
consistently been identified in genome-wide association studies.88 Although most of these 
novel risk alleles have a high frequency in the population, they have been shown to contribute 
to a small increase in the VTE risk,88 and are estimated to explain only 5% of the observed 
heritability of VTE.88, 98 Consequently, the vast majority of the genetic susceptibility to VTE 
remains unknown. Hopefully, recent genetic strategies such as next-generation sequencing 
and whole exome and genome sequencing will reveal yet unknown genetic variants 
influencing the risk of VTE.88 
 
1.3.2 Acquired risk factors 
Numerous acquired risk factors for VTE are presently known. Advancing age is an 
established risk factor for VTE, and the incidence of VTE has consistently been shown to rise 
exponentially with increasing age.9, 11, 13, 14  Subjects aged 70 years or older had more than 11 
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times increased risk of VTE compared with subjects below 50 years of age in the Tromsø 
Study14 and more than 3 times higher risk of VTE than those aged 45 to 69 years in the 
Helseundersøkelsen Nord-Trøndelag (HUNT) Study.9 The increase in VTE risk associated 
with increasing age could be explained by accumulation of conventional risk factors for VTE 
with advancing age (e.g. comorbid conditions or hypercoagulability due to increased plasma 
pro-coagulants and reduced coagulation inhibitors), age-specific risk factors (e.g. endothelial 
dysfunction or venous stasis), or a synergistic effect of age with other established risk factors 
for VTE.38, 99, 100 
The results regarding the association between sex and VTE are conflicting. Some 
studies have found similar overall incidence of VTE in men and women,16, 101 whereas most 
studies have shown a higher overall risk of VTE in men.11, 13, 102-104 Moreover, middle-aged 
and elderly men had higher risk of VTE than women of the same age,9, 13, 14 whereas women 
had higher risk of VTE than men during childbearing years in some studies.9, 13, 105 However, 
the risk of VTE was 2 times higher in men than women when female reproductive risk factors 
were taken into account in the Multiple Environmental and Genetic Assessment of Risk 
Factors for Venous Thrombosis (MEGA) Study,106 supporting that male sex also is a risk 
factor for first VTE.  
Body height, pregnancy and endogenous or exogenous hormones may contribute to 
the observed difference in VTE incidence in men and women. Tall stature has been identified 
as a risk factor for VTE in men,104, 107 and the risk of VTE in men increased by 34% per 10 
cm increase in height in the Tromsø Study.107 An association between pregnancy and VTE 
has consistently been reported, and pregnancy has been found to increase the VTE risk 4 to 5–
fold.91, 108 Specifically, the highest VTE risk associated with pregnancy has been shown 
during the postpartum period (i.e. the first 3 months after delivery)91, 108 and in women with 
thrombophilia.91 In addition, oral contraceptives are established risk factors for VTE in 
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women,94, 109, 110 and have been shown to increase the risk of VTE 2 to 7 times, especially the 
first months of use.94, 110 An association between oral contraceptives and VTE may be 
explained by an acquired APC resistance found in women commencing oral contraceptives.111 
Furthermore, hormone replacement therapy (i.e. with estrogens) in postmenopausal women 
has been reported to increase the risk of VTE 2 to 3 fold.112, 113 
Institutionalization (i.e. admittance to a hospital or nursing home) has also been 
proven an important risk factor for VTE,11, 15, 62 and accounted for more than 50% of the VTE 
events in the population.11, 62 Recent hospitalization has been shown to increase the risk of 
VTE 6- to 8-fold,114, 115 and the incidence of in-hospital VTE was more than 100 times higher 
than the incidence of VTE in community residents in a general population.116 Accordingly, 
recognition of hospitalized patients in need of VTE prophylaxis should be emphasized. In 
order to improve identification of hospitalized patients at high risk of VTE, the Padua 
Prediction Score for VTE has been proposed.117 In this prediction model, 11 VTE predictors 
are included, and those with a cumulative score ≥ 4 (i.e. 3 points each for active cancer, 
previous VTE, reduced mobility and known thrombophilia, 2 points for recent trauma and/or 
surgery, and 1 point each for age ≥ 70, heart and/or respiratory failure, acute MI or ischemic 
stroke, acute infection and/or rheumatologic disorder, obesity and ongoing hormonal 
treatment) are defined as high risk patients in need of VTE prophylaxis.117 A high risk of VTE 
according to the Padua Prediction Score has been demonstrated in 40% of hospitalized 
medical patients,117 and medical prophylaxis of VTE has been found to significantly reduce 
the risk of VTE by 50 to 70%.118-120 Therefore, VTE prophylaxis is recommended for 
hospitalized patients at high risk of VTE without the risk of bleeding.109, 121 Furthermore, VTE 
treatment has been recognized as a huge economic burden for a hospital, associated with 4 
times higher costs compared with VTE prophylaxis.122 Still, a systematic review revealed that 
less than 20% of patients receive the appropriate VTE prophylaxis.123 
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The substantial impact of institutionalization on the incidence of VTE may be 
explained by comorbidities, surgery, trauma or immobilization. Several comorbid conditions 
and treatments, such as lower-extremity fractures and casts,11 heart failure,11, 15, 62 chronic 
obstructive pulmonary disease,15 neurological diseases,13 acute infections,121 rheumatic and 
autoimmune diseases,11, 15 kidney diseases,11, 15 previous VTE,56 superficial vein thrombosis,13 
varicose veins,115 venous compression (e.g. by a mass or hematoma)11 and cancer,11, 13, 15 have 
been recognized as independent risk factor for VTE. Cancer has been acknowledged as a 
major cause of VTE, and was present in 20-30% of VTE patients.9, 124, 125 Overall, 4 to 7 times 
increased risk of VTE has been shown in cancer patients compared with subjects without 
cancer,115, 126-129 and VTE has been reported to occur in up to 10% of cancer patients.129-133 
The risk of VTE associated with cancer varies according to cancer site, severity and therapy 
and with time from the cancer diagnosis. The highest VTE risk has been found in patients 
with pancreatic, brain, lung, gastro intestinal and metastatic cancer,126-130, 132, 134 cancer 
patients receiving chemotherapy,126, 132 and during the initial months following the cancer 
diagnosis.126-128, 130 Cancer has been shown to elevate levels of several pro-coagulant factors, 
such as TF, FV, FVII and FVIII,135, 136 and cause activation and aggregation of platelets.137, 138 
This may in part explain the increased risk of VTE associated with cancer. Moreover, venous 
stasis and vessel wall injury due to tumor growth may contribute to VTE risk in cancer 
patients.139 
Recent surgery and trauma have also repeatedly been reported as independent risk 
factors for VTE,11, 15, 115 and were associated with 13 to 22-fold increased VTE risk in a 
general population.115, 116 A particularly high risk of VTE has been found for invasive 
neurosurgery, urological, vascular and orthopedic surgeries,140 and the incidence of VTE has 
been shown to increase with increasing trauma severity.141 Furthermore, minor surgical 
procedures including central venous catheter and pacemaker insertions have also been 
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identified as risk factors for VTE.62, 115 Finally, marked immobility has been shown to 
increase the risk of VTE,11 and both general immobility142 and immobilization during 
traveling143 have been reported to nearly double the VTE risk. 
 
1.4 Traditional atherosclerotic risk factors and the risk of venous thromboembolism 
The association between traditional atherosclerotic risk factors (e.g. hypertension, 
dyslipidemia, diabetes mellitus and smoking) and VTE has extensively been explored, and the 
results are partly conflicting. Diabetes mellitus has been identified as a risk factor for VTE in 
some studies,102, 144 and increased the risk of VTE 2-fold after adjusting for age and sex in a 
cohort study.102 However, the majority of prospective cohort studies have failed to find an 
independent association between diabetes mellitus or high glucose levels and VTE.103, 145-147 
In a recently published meta-analysis including nearly 250 000 participants from prospective 
studies, an initially observed association between diabetes mellitus and VTE disappeared after 
adjusting for BMI.148 This suggests that that an apparent association between diabetes mellitus 
and VTE is explained by obesity. Similarly, hypertension was associated with VTE risk in 
some studies,103, 149 whereas most prospective cohorts and the aforementioned meta-analysis 
have shown that there is no association between hypertension and VTE after taking potential 
explanatory factors such as age, sex and obesity into account.102, 146-148 
Results regarding the link between dyslipidemia, smoking, alcohol consumption and 
physical activity and VTE are also conflicting. In some studies, levels of low-density 
lipoprotein (LDL) and high-density lipoprotein (HDL) cholesterol and triglycerides 
influenced the incidence of VTE.103, 147, 150 Nevertheless, the majority of prospective cohorts 
and the recently published meta-analysis have reported that dyslipidemia, including elevated 
total cholesterol, LDL cholesterol and triglycerides and low HDL cholesterol, was not 
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independently associated with VTE.102, 146, 148 Cigarette smoking has been shown to increase 
the risk of VTE 1.2 to 4.3-fold,103, 147, 148, 151 and in the Diet, Cancer and Health (DCH) Study, 
a positive dose-response relationship was found between current cigarette smoking and the 
risk of VTE.152 In contrast, other studies have failed to identify cigarette smoking as an 
independent risk factor for VTE.102, 149 In the Tromsø Study, an initially observed association 
between increasing number of pack-years and provoked VTE disappeared after cancer and MI 
were taken into consideration.153 This implies that an apparent association between smoking 
and VTE may be mediated by MI or cancer. 
Most studies have shown that alcohol consumption is not a risk factor for VTE.102, 103, 
147 In the Tromsø Study, total alcohol consumption was not associated with increased risk of 
VTE, but sub-analyses revealed that liquor and wine consumption had an impact on the VTE 
risk.154 Moderate physical activity has been found to protect against VTE, whereas strenuous 
or overall physical activity has been reported to increase the risk of VTE in some prospective 
cohorts.147, 155 In contrast, other prospective cohorts have reported that physical activity is not 
associated with increased risk of VTE.102, 103 In the Tromsø Study, overall physical activity 
was not associated with VTE, but strenuous physical activity increased the risk of VTE in the 
elderly, and moderate exercise was associated with a borderline significant decrease in VTE 
risk in young and lean subjects.156 
 Obesity is according to the World Health Organization (WHO) defined as BMI ≥ 
30,157 and has a reported prevalence of 13%157 and 25%158 in the adult population of the 
World and Norway, respectively. Obesity is the only traditional atherosclerotic risk factor, 
aside from advancing age, consistently reported as a risk factor for VTE,144 and BMI ≥ 30 has 
been shown to increase the risk of VTE 1.5 to 3.1-fold.102, 103, 147, 159-161 In agreement with this, 
advancing BMI and age were the only shared risk factors for VTE and MI when the influence 
of atherosclerotic risk factors on the risk of VTE and MI was investigated in the same 
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population.101, 162 Moreover, high body weight,160 total body fat,160 waist159-161 and hip 
circumference,159-161 and waist-hip103, 159, 161 and waist-height ratio161 have also been identified 
as independent risk factors for VTE. In the Tromsø Study, waist circumference was the 
anthropometric measure found to identify most obesity-related VTE events.159, 161 
 Obesity is believed to mediate VTE risk through venous stasis, hypercoagulability, 
release of adipokines, or chronic low-grade inflammation. Venous stasis has been shown to 
accompany abdominal obesity due to increased intra-abdominal pressure,163, 164 and increased 
levels of pro-coagulant factors (e.g. FVIII, vWF and fibrinogen) and decreased fibrinolytic 
activity has been found in obese.165 Moreover, adipose tissue secrets adipokines which have 
been shown to increase the risk of venous disease.166 Finally, chronic inflammation resulting 
from obesity167 may increase the risk of VTE.149, 168-171 In accordance with this, adjustments 
for high-sensitivity C-reactive protein (hs-CRP) attenuated the observed association between 
obesity and VTE in the Tromsø Study.168 
 
1.5 Arterial cardiovascular disease and the risk of venous thromboembolism 
VTE and arterial cardiovascular diseases (CVD) have traditionally been considered as a 
separate diseases with distinct pathophysiology and treatment strategies. However, results of 
emerging studies point to a potential interrelation between arterial and venous thrombosis. 
Few prospective cohorts have investigated the potential link between arterial thrombotic 
diseases and future risk of VTE, and the results of existing publications are diverging. An 
association between coronary heart disease and PE has been described in patients aged 60 
years or older.172 Furthermore, MI was associated with 2 times increased risk of subsequent 
VTE in a trial of postmenopausal women, whereas no association was found between stroke 
or transient ischemic attack and future VTE.114 In contrast, atherothrombosis in cervico-
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cranial and peripheral arteries but not in coronary arteries was associated with increased VTE 
risk in an autopsy study.173 Moreover, incident coronary heart disease and stroke was 
associated with a 51% increased risk of future VTE in the Atherosclerosis Risk in 
Communities (ARIC) Study,174 whereas a lower risk of VTE was found in those diagnosed 
with arterial thrombotic events after adjusting for traditional atherosclerotic risk factors in the 
Cardiovascular Health Study (CHS).175  
 Large Danish population-based registry-studies have demonstrated that 
hospitalizations for MI or stroke176 and heart disease177 were associated with substantially 
increased risk of VTE in the subsequent 3 months after taking age, sex and information 
regarding obesity, medication use and comorbidities from the Danish National Patient 
Registry into consideration. In a more recent study, incident acute MI was associated with 
84% increased odds of incident VTE, but the association between MI and VTE disappeared 
after adjusting for traditional atherosclerotic and VTE risk factors, medication use and 
comorbidities.178 The results from these studies should however be interpreted with some 
caution, as they have limited information on potential confounders, limited validation of both 
the exposure (arterial CVD) and outcome (i.e. VTE) of interest,176, 177 or applied a 
retrospective design.176-178 Consequently, prospective studies with validated information on 
exposure, outcome and potential confounders are needed. 
 
1.6 Venous thromboembolism and the risk of arterial cardiovascular disease 
Approximately 30% higher number of deaths from MI or ischemic stroke has been found in 
VTE patients than in the general population,179 and growing evidence supports an interrelation 
between VTE and subsequent arterial CVD. An association between unprovoked VTE and 
future arterial thrombotic events has been described in several studies of VTE patients,180-185 
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and a 3- and 1.6- fold higher risk of arterial thrombosis has been found after adjusting for 
traditional atherosclerotic risk factors in unprovoked VTE patients compared with subjects 
without VTE from the general population182 and provoked VTE patients,181 respectively. 
Similarly, a higher frequency of arterial thrombotic events has been shown in patients with 
unprovoked than provoked PE180, 184 and controls without PE.184 However, the risk of arterial 
CVD in the aforementioned studies was assessed in selected cohorts (e.g. included VTE 
patients without permanent risk factors for VTE,180 or did not include those with a short life-
expectancy180, 181 or controls from the general population180, 181, 184), or included a low number 
of study participants.182 
 A large population-based cohort from the Netherlands reported a 42% higher risk of 
MI, ischemic stroke and cardiovascular death combined after a VTE diagnosis, and showed 
that the association between VTE and future arterial thrombotic events only applied to 
unprovoked VTE.186 However, subjects with previous VTE were not excluded in this study, 
and the impact of incident VTE on the risk of arterial CVD was not investigated.186 Incident 
VTE was a substantial marker of subsequent arterial CVD risk during 20 years of follow-up in 
a large Danish population-based registry-study including more than 200 000 subjects.187 In 
this study, the risk estimates of arterial CVD were similar for provoked and unprovoked 
VTE.187 Nevertheless, information about potential confounders such as BMI was not 
available.187 
An association between incident VTE and future arterial CVD was further confirmed 
in the MEGA study, in which VTE was associated with approximately 2 times increased risk 
of subsequent arterial CVD.188 VTE patients had nearly 3 times higher risk of MI than 
controls from the general population without VTE after taking anticoagulant therapy, age, sex, 
BMI, smoking, chronic diseases and malignancy into account in this study, whereas no 
independent association was found between incident VTE and future ischemic stroke.188 
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However, information regarding arterial thrombotic diseases was based on discharge 
diagnoses only and not validated in the MEGA Study.188 Therefore, further population-based 
studies with validated information regarding potential confounders and validated exposure 
and outcome events are needed. 
 
1.7 Family history of myocardial infarction and the risk of venous thromboembolism 
A family history of heart disease is an established risk factor with a 2-fold increased risk of 
MI.189-191 The risk of MI increases with increasing number of first degree relatives with a 
history of heart disease189, 190, 192 and is particularly high for those with relatives diagnosed 
with MI at a young age.192, 193 Moreover, family history of MI has been shown to interact with 
other atherosclerotic risk factors on the risk of MI.190-192  
 A high genetic correlation between arterial and venous thrombotic diseases has been 
demonstrated,65 and it has therefore been proposed that family history of MI may also 
increase the risk of VTE. An association between family history of MI and VTE has been 
confirmed in the Tromsø Study and the HUNT Study, in which subjects with at least one first 
degree relative with a history of MI before 60 years of age had approximately 30% increased 
risk of incident VTE after adjustment for other traditional atherosclerotic risk factors.14, 149 
Similarly, family history of MI was associated with 30% increased odds of VTE, and a 
particularly high risk of VTE was found in subjects with relatives with MI before the age of 
50 years in the Genetic Attributes and Thrombosis Epidemiology (GATE) Study.194 In 
contrast, subjects with a parental history of MI had only 3% increased risk of VTE and no 
association was found between a history of MI in a sibling and VTE risk in a registry-based 
study.195 However, the results of this study are limited by lack of a prospective design, 
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validated VTE events and information regarding traditional atherosclerotic risk factors other 
than age and sex.195 
Potentially, the association between family history of MI and VTE is explained by 
aggregation of common atherosclerotic risk factors or other shared genetic or environmental 
risk factors for MI and VTE. Furthermore, the observed association between MI and 
subsequent VTE176, 177 could imply that the interrelation between family history of MI and 
VTE is mediated by MI. However, the mechanism for which family history of MI increases 
risk of VTE has not been assessed in previous studies. 
 
1.8 Venous thromboembolism and the risk of atherosclerosis 
Atherosclerosis is a chronic disease of the inner lining of arterial walls resulting in formation 
of atheromatous plaques.196 The atheromatous plaques contain lipids, foam cells, leukocytes 
and smooth muscles cells covered by a fibrous cap that may rupture or obstruct the vessel 
lumen and cause arterial CVD.196 Atherosclerosis is frequently measured by ultrasound 
assessments of carotid plaque presence and intima-media thickness (IMT), and was present in 
25% of adults in a general population.197 Presence of carotid plaques198, 199 and high IMT198, 
200-205 have been identified as independent risk factors for MI and stroke, and improve the 
prediction of arterial CVD risk. Moreover, the risks of MI and stroke have been found to 
increase with 26% and 31%, respectively, per one standard deviation increase in IMT,202 and 
to increase with advancing carotid plaque burden.199 However, a meta-analysis of population-
based studies showed that carotid plaques had higher accuracy for predicting arterial CVD 
than IMT,206 and in prospective cohorts, carotid plaques, but not carotid IMT, were predictors 
of coronary heart disease.198, 207 
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 Prandoni and coworkers were the first to demonstrate increased odds of plaques and 
high IMT on carotid ultrasound in unprovoked DVT patients after taking traditional 
atherosclerotic risk factors into account in a case-control study.208 Based on these findings, an 
independent link between unprovoked VTE and subclinical atherosclerosis was proposed. An 
association between unprovoked VTE and atherosclerosis was confirmed in subsequent case-
control studies, in which unprovoked VTE patients had substantially higher frequency of 
coronary artery calcification on CT angiography209 and higher IMT and prevalence of plaques 
on carotid and femoral ultrasound210 than controls after adjusting for traditional 
atherosclerotic risk factors. Furthermore, subjects above 50 years of age with unprovoked 
VTE had 15-fold increased odds of symptomatic and subclinical atherosclerosis, assessed by 
carotid IMT and plaque presence, in a case-control study.211 In this study, provoked VTE was 
also associated with carotid atherosclerosis, but to a lesser extent than unprovoked VTE.211 In 
contrast, provoked DVT has previously been shown to not increase the risk of 
atherosclerosis.208, 212 An independent association between VTE and atherosclerosis may 
imply that atherosclerosis mediates the observed link between VTE and future arterial 
CVD.187 However, the aforementioned case-control studies were not designed to explore the 
temporal sequence between VTE and subsequent atherosclerosis. 
 Prospective studies have failed to demonstrate increased risk of VTE in subjects with 
subclinical atherosclerosis.174, 175, 213 No subclinical atherosclerosis measure was associated 
with increased risk of VTE in the ARIC Study.174 Moreover, high risk carotid plaques 
decreased the risk of VTE by 35% in the CHS,175 and in the Tromsø Study, increasing carotid 
IMT and total plaque area (TPA) increased the risk of future MI but not VTE in analyses 
adjusted for traditional atherosclerotic risk factors.213 Carotid atherosclerosis was only 
measured at baseline and not updated during follow-up in the aforementioned cohorts.174, 175, 
213 Therefore, regression dilution bias may be present and potentially conceal a weak 
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association between atherosclerosis and subsequent VTE in these studies. Consequently, 
further studies with repeated carotid atherosclerosis measurements are warranted. A history of 
VTE was not significantly associated with preclinical atherosclerosis in a cohort of 
thrombophilia patients, although a borderline significant association was found between a 
history of VTE and IMT.214 However, the association between incident VTE and subsequent 
carotid atherosclerosis has not been explored in a general population, and the potential impact 
of atherosclerosis on the observed association between incident VTE and future arterial CVD 
remains unsettled.  
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2. Aims of the thesis 
The overall aims of this thesis were to investigate the bidirectional association between 
venous thromboembolism and arterial cardiovascular diseases, and to identify shared risk 
factors underlying this association. 
The specific aims of the thesis were: 
A: To investigate the association between myocardial infarction and the future risk of venous 
thromboembolism in a population-based cohort with validated information on the exposure, 
the endpoint, and potential confounders (Paper I).  
B: To investigate the association between incident venous thromboembolism and future risk 
of arterial thromboembolic events in a general population (Paper II). 
C: To determine the absolute and relative risks of myocardial infarction and venous 
thromboembolism by family history of myocardial infarction in a population-based cohort 
study (Paper III). 
D: To compare the effect of family history of myocardial infarction on risks of myocardial 
infarction and venous thromboembolism explicitly by applying a cause-specific model, and 
explore whether the association between family history of MI and VTE could be explained by 
atherosclerotic risk factors (Paper III). 
E: To investigate whether incident venous thromboembolism was associated with subsequent 
formation and progression of carotid atherosclerosis, and whether this possible association 
was mediated by low-grade inflammation in a population-based matched cohort study (Paper 
IV).  
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3. Study populations and methods 
3.1 The Tromsø Study 
The Tromsø Study is a single-center, population-based cohort study with repeated health 
surveys of inhabitants of Tromsø, Norway. It was initiated in 1974 to investigate potential 
explanations for the high cardiovascular mortality observed in Northern Norway in the 
1970s.215 Since the initiation, seven surveys have presently been conducted, and a wide range 
of chronic diseases has been included in the Tromsø Study. The fourth, fifth and sixth surveys 
of the Tromsø Study (Tromsø 4, 5 and 6, respectively) were conducted in 1994-95, 2001-02 
and 2007-08, respectively. Tromsø 4 is the largest survey of the Tromsø Study. To this 
survey, all inhabitants aged 25 years or older living in Tromsø were invited, and 27 158 
(77%) participated. Subjects aged 55-74 years and 5-10% of subjects in other 5-year age 
groups were offered a more extensive screening, to which 7 965 (78%) participated. Subjects 
attending the extensive screening in Tromsø 4 who were still alive and had not moved from 
Tromsø were re-invited to participate in Tromsø 5 and 6. In addition, random samples within 
different age groups of the Tromsø population were invited to participate in Tromsø 5 and 6, 
and 8 130 (79%) and 12 984 (66%) participated in these surveys, respectively. An extensive 
screening similar to the one in Tromsø 4 was conducted in Tromsø 5 and 6. 
 
3.2 The Diet, Cancer and Health Study 
The Diet, Cancer and Health Study was conducted in 1993-97 and is a prospective, 
population-based cohort study aiming to assess the interrelations between diet, lifestyle and 
cancer.216 To the DCH Study, all inhabitants living in the urban areas of Copenhagen and 
Aarhus, Denmark, were identified from a computerized record of the Civil Registration 
System and invited by mail if they were born in Denmark, between 50 to 65 years of age and 
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did not have a cancer diagnosis in the Danish Cancer Registry at enrollment. In total, 57 054 
(35%) participated. 
 
3.3 Study designs 
Paper II in the thesis was based on data from Tromsø 4 and the DCH, paper III was based on 
data from Tromsø 4 and 5, and papers I and IV were based on data from Tromsø 4-6. In 
papers I and III, the subjects were followed from the date of enrollment in the Tromsø Study 
through December 31, 2010. In paper II, the participants were followed from the date of 
enrollment in Tromsø 4 or the DCH Study and followed through December 31, 2010 and 
April 30, 2008, respectively. The participants in paper IV were followed from the date of 
enrollment in the Tromsø Study to the second carotid ultrasound in the extensive screenings 
in 2001-02 or 2007-08.  
 
3.4 Baseline measurements 
In the Tromsø and DCH Studies, baseline information was collected by self-administered 
questionnaires, blood samples and physical examinations. Questionnaires were used to obtain 
information on current smoking, physical activity, education level, hypertension, 
hypercholesterolemia, diabetes mellitus, cancer, MI, stroke, family history of coronary heart 
disease or MI, and medication use including hormone replacement therapy, oral 
contraceptives, anti-hypertensives and lipid-lowering drugs. Height and weight were 
measured with light clothing and without shoes, and BMI calculated as weight in kilograms 
divided by the square of height in meters (kg/m2). Obesity was classified according to the 
WHO definition (i.e. BMI ≥30).157 
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In the Tromsø Study, systolic and diastolic blood pressures were measured three times 
by trained personnel on the upper right arm at one minute intervals with an automatic device 
(Dinamap Vital Signs Monitor, 1846, Critikon, Tampa, Florida, USA) with the participant in 
a sitting position after two minutes of rest, and defined as the mean of the last two 
measurements. Non-fasting blood samples were collected from an antecubital vein. Serum 
was prepared by centrifugation after 1 hour in room temperature, and analyzed at the 
Department of Clinical Chemistry, University Hospital of North Norway (UNN), Tromsø, 
Norway. Total serum cholesterol was analyzed by use of an enzymatic colorimetric method 
with a commercially available kit (CHOD-PAP, Boehringer-Mannheim, Mannheim, 
Germany). Serum HDL cholesterol was measured after precipitation of lower-density 
lipoproteins with heparin and manganese chloride.  
hs-CRP was measured after storage at -70 °C in Tromsø 4 and -20 °C in Tromsø 5 and 
6, by a particle-enhanced immunoturbidimetric assay on a Modular P (Tromsø 4 and 6) or 
Hiatchi 917 (Tromsø 5) autoanalyzer (Roche Hiatchi, Mannheim, Germany), using reagents 
from Roche Diagnostics (Mannheim, Germany). Samples from Tromsø 4 were analyzed after 
12 years of storage, and samples from Tromsø 5 and 6 were analyzed in batches at the time of 
the surveys. In Tromsø 6, hs-CRP was measured at 2 different time points, and if both 
measurements were available, the average was recorded. The lower detection limit of the hs-
CRP assay was 0.03 mg/L. Blood pressure and blood samples in the DCH Study were 
collected and analyzed in similar ways.160 Hypertension was classified as mean systolic blood 
pressure ≥ 140 mmHg, mean diastolic blood pressure ≥ 90 mmHg, self-reported use of blood 
pressure lowering drugs, or self-reported hypertension. Hypercholesterolemia was classified 
as total serum cholesterol ≥ 6.5 mmol/l, self-reported use of lipid lowering drugs, or self-
reported hypercholesterolemia. 
   34 
 
3.4.1 Family history of myocardial infarction 
To identify family history of MI, subjects in the Tromsø Study were asked to report whether 
their mother, father, sister, brother, child, or none in the family had a history of MI before the 
age of 60 years. A positive family history was regarded as at least one first degree relative 
with a history of MI before the age of 60 years. 
  
3.5 Outcome measurements 
3.5.1 Venous thromboembolism 
In the Tromsø Study, all first-time VTE events during follow-up were identified by searching 
the hospital discharge diagnosis registry, the autopsy registry, and the radiology procedure 
registry of UNN.107 UNN is the only hospital in the Tromsø region, and all hospital care and 
relevant radiological procedures are offered here. The relevant discharge diagnosis codes 
were the International Classification of Diseases (ICD)-9 codes 325, 415.1, 451, 452, 453, 
671.3, 671.4 and 671.9 for the period 1994-98 and the ICD-10 codes I26, I80, I81, I82, 167.2, 
O22.5, O87.1 and O87.3 for the period 1999-2012. The medical record for each potential 
VTE case was reviewed by trained personnel. A VTE event was only verified and recorded 
when presence of clinical signs and symptoms of DVT or PE were combined with an 
objective confirmatory radiology procedure (i.e. compression ultrasound, venography, CT, 
perfusion-ventilation scan, pulmonary angiography, or autopsy), and resulted in a VTE 
diagnosis made by a physician in the medical record that required treatment (i.e. anticoagulant 
treatment with LMWH, VKA or similar agents, thrombolytics or vascular surgery). For 
patients derived from the autopsy registry, a VTE-event was recorded when the autopsy 
record indicated PE as the cause of death or as a significant condition contributing to death. 
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 In the DCH Study, all incident VTE events during follow-up were identified by 
linking the cohort with the Danish National Patient Registry and the Danish National Death 
Registry by use of the unique civil registration number of the study participants.160 The 
Danish National Patient Registry contains nationwide data on all non-psychiatric admissions 
and discharges from emergency departments and outpatient clinics. The relevant discharge 
diagnosis codes were the ICD-8 codes 450.99, 451.00, 451.08, 451.09 and 451.99, and the 
ICD-10 codes I26 and I80.2 through I80.9. Trained personnel reviewed the medical records 
for each potential VTE-case. A VTE diagnosis was only verified and recorded when typical 
clinical symptoms of VTE were combined with confirmatory diagnostic test results (i.e. 
ultrasound, venography, CT, perfusion-ventilation scan or echocardiography), or when 
autopsy verified VTE. 
Concurrent DVT and PE were registered as PE, and verified VTE events were 
classified as unprovoked or provoked based on the presence of provoking factors at the time 
of diagnosis. In the Tromsø Study, a VTE event was defined as provoked if one or more of 
the following factors were present: recent surgery or trauma within the previous 8 weeks 
before the VTE event, acute medical conditions (e.g. acute MI, stroke or major infectious 
disease), active cancer at the time of the VTE event, marked immobilization (i.e. bed rest for 
> 3 days, wheelchair use, or long-distance travel exceeding 4 hours within the last 14 days) or 
any other factor described by a physician in the medical record (e.g. intravascular catheter).107 
A similar classification of the VTE events was performed in the DCH Study.160 However, in 
the last update of VTE events in the DCH Study (July 2006 to April 2008), verified VTEs 
were not further classified. 
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3.5.2 Myocardial infarction 
In the Tromsø Study, all first-time hospital and out-of-hospital events of MI during follow-up 
were identified by searching medical records, autopsy records and death certificates.101 The 
national unique 11-digit identification number allowed linkage to national and local diagnosis 
registries and to the National Causes of Death Registry at Statistics Norway. The relevant 
diagnosis codes in the discharge diagnosis registry at UNN and in the National Causes of 
Death Registry were the ICD-8 codes 410-414, 427, 430-438 and 795-796 for the period 
1969-1980, ICD-9 codes 410- 414, 427, 430-438 and 799 for the period 1980-98, and the 
ICD-10 codes I20-I25, I47.1, I48, I60-I69, R96, R98 and R99 thereafter. Medical records 
were case validated by an independent endpoint committee. Modified WHO 
MONICA/MORGAM criteria for MI were used, and these included clinical symptoms and 
signs, findings in electrocardiograms, values of cardiac biomarkers, and autopsy reports when 
applicable. Linkage to the National Causes of Death Registry at Statistics Norway allowed 
identification of fatal MI events that occurred as out-of-hospital deaths, including deaths that 
occurred outside Tromsø. The death certificates were used to collect relevant information on 
the MI events from additional sources, such as autopsy reports and records from nursing 
homes, ambulance services and general practitioners. 
 In the DCH Study, potential cases of incident MI during follow-up were identified by 
linkage to the Danish National Patient Registry and the Danish Causes of Death Registry by 
use of the civil registry number unique to every Danish citizen.217 The relevant discharge 
diagnosis codes were ICD-8 codes 410 to 410.99 and 427.27, and ICD-10 codes I21.0 to I21.9 
and I46.0 to I46.9. From baseline through 2003, potential MI cases were validated by direct 
review of medical records in accordance with the guidelines of the American Heart 
Association and the European Society of Cardiology for use in epidemiology.218 From 
January 2004 until end of follow up in April 2008, and for participants whose medical records 
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were not available for review in the period 1993-2003, all participants with a diagnosis of MI 
were accepted as cases without further validation. These diagnoses had a positive predictive 
value above 90% in the Danish National Patient Registry.218 
 
3.5.3 Ischemic stroke 
In the Tromsø Study, all incident hospital and out-of-hospital ischemic stroke events during 
follow-up were identified by searching medical records, autopsy records and death 
certificates.219 The national unique 11-digit identification number allowed linkage to national 
and local diagnosis registries and to the National Causes of Death Registry at Statistics 
Norway. The relevant discharge diagnosis codes in the discharge diagnosis registry at UNN 
and the National Causes of Death Registry were the ICD-8 and -9 codes 430-438 and the 
ICD-10 codes I60-I69. In addition, manual and/or electronic text searches of hospital records 
for notes on stroke were performed in all participants with ICD-8 and -9 diagnosis codes 410- 
414, 427 and 798-799, and ICD-10 diagnosis codes I20-I25, I47.1, I48, R96, R98 and R99 to 
ensure case completeness. Medical records were retrieved for case validation by an 
independent endpoint committee. Ischemic stroke was defined according to the WHO 
definition (i.e. an acute disturbance of focal or global cerebral function with symptoms lasting 
≥ 24 hours or leading to death of presumed vascular origin),220 and only validated and 
recorded when CT or magnetic resonance image (MRI) scans had ruled out brain hemorrhage. 
In the DCH Study, potential cases of incident ischemic stroke during follow-up were 
identified by linkage to the Danish National Patient Registry and the Danish Causes of Death 
Registry by use of the civil registry number of the study participants.221 The relevant 
discharge diagnosis codes were ICD-10 codes I60 to 69.8 and G45. Medical records of each 
potential ischemic stroke event were reviewed by a physician experienced in stroke medicine 
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without knowledge of the baseline information of the potential cases. The WHO definition of 
ischemic stroke was used220 and an ischemic stroke event was only validated and recorded 
when symptoms were consistent with stroke, and CT, MRI, spinal fluid examination or 
autopsy had excluded brain hemorrhage. 
 
3.5.4 Carotid atherosclerosis 
High-resolution B-mode and color/pulsed-wave Doppler ultrasonography of the right carotid 
artery were performed in the extensive screenings in Tromsø 4, 5 and 6 by trained personnel 
who had completed a two month pre-study training protocol to ensure equal and standardized 
examination techniques and measurement procedures.222-224 All sonographers followed 
identical scanning and reading procedures and used an Acuson XP10 128 ART ultrasound 
scanner equipped with a 7.5 MHz linear transducer in Tromsø 4 and 5, and a GE Vivid 7 
ultrasound scanner with a linear 12 MHz transducer in Tromsø 6. Plaques were registered in 
the near and far walls of the common carotid artery, the bifurcation and the internal carotid 
artery (6 locations). A plaque was defined as a local protrusion of the vessel wall into the 
lumen of ≥ 50% compared with adjacent IMT. For each plaque, a still image was recorded 
and digitized using the Matrix Meteor II frame-grabber and Matrox Intellicam. Adobe 
Photoshop 7.0 was subsequently used to measure plaque areas by outlining the perimeter of 
each plaque with a cursor, and the plaque area was calculated as pixel values. For the 
resolution used in the present thesis, a plaque area of 167 pixels corresponded to 1 mm2. In 
subjects with more than one plaque, TPA was calculated as the sum of all plaque areas. Novel 
plaque formation was defined as development of new plaques at the second ultrasound in 
vessels without plaques at the first ultrasound. Plaque progression was defined as an increase 
in TPA between the first and second ultrasound.  
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4. Main results 
4.1 Paper I: Impact of incident myocardial infarction on the risk of venous 
thromboembolism: the Tromsø Study 
Population-based registry-studies have shown that patients with a history of MI are at 
increased short-term risk of subsequent VTE.176, 177 The purpose of this study was to examine 
the association between incident MI and VTE in a prospective population-based cohort, using 
Cox regression models with age as the scale time, VTE as outcome, MI as a time-dependent 
variable and sex, BMI, blood pressure, diabetes mellitus, HDL cholesterol, smoking, physical 
activity, and education level as covariates. The study participants were 29 506 subjects 
attending the fourth, fifth and/or sixth surveys of the Tromsø Study in 1994-95, 2001-02 and 
2007-08, respectively. Incident MI and VTE events were recorded until December 31, 2010. 
Non-MI-exposed and MI-exposed failure time was counted from the date of enrollment to the 
date of VTE, death, migration or the end of the study period, whichever came first. During a 
median follow-up of 15.7 years, 1 892 participants experienced MI and 699 experienced VTE. 
MI was associated with a 51% increased risk of VTE (HR 1.51; 95% CI 1.09-2.11), a 83% 
increased risk of provoked VTE (HR 1.83; 95% CI 1.21-2.79) and a 72% increased risk of PE 
(HR 1.72; 95% CI 1.07-2.79), but not significantly associated with the risk of DVT or 
unprovoked events. MI explained 6.2% of the PEs in the population and 78.5% of the PE risk 
in MI patients. The risk of VTE was high immediately after MI, and the highest risk estimates 
for PE were observed during the first 6 months following the MI (HR 8.49; 95% CI 4.00-
18.77). Thereafter, the VTE risk rapidly declined, and the association between MI and 
subsequent PE disappeared after 1 year following the MI event. In conclusion, our findings 
indicate that MI is associated with a transient increased VTE risk, independently of traditional 
atherosclerotic risk factors, and the risk estimates were particularly high for PE.  
   40 
 
4.2 Paper II: Impact of incident venous thromboembolism on risk of arterial thrombotic 
diseases 
A previous registry-based study has found substantially increased long-term risk of 
hospitalization for arterial CVD in VTE patients.187 The aims of this study were to investigate 
the association between VTE and future arterial events, and to determine the population 
attributable risk of arterial events by VTE in a large prospective cohort recruited from the 
general population. The study participants were 81 687 subjects attending the Tromsø Study 
in 1994-95 or the Diet, Cancer and Health Study in 1993-97. Incident VTE, MI and ischemic 
stroke were registered until December 31, 2010 and April 30 2008 in the Tromsø and DCH 
Studies, respectively. Non-VTE-exposed and VTE-exposed failure times were calculated 
from the date of enrollment to the date of MI, ischemic stroke, death, migration or end of the 
study, whichever came first. There were 1 208 cases of VTE and 90 subsequent arterial events 
during a median follow-up of 12.2 years. Incident VTE was associated with 35% increased 
risk of subsequent arterial thrombotic disease (HR 1.35; 95% CI 1.09-1.66). The association 
between VTE and arterial events only applied to PE, which was associated with 82% 
increased risk of future arterial CVD (HR 1.82; 95% CI 1.35-2.47). The highest incidence of 
arterial events was found the first year after a PE event. Only 0.9% of the arterial events were 
attributed to VTE, and the VTE explained 63.8% of the arterial events among VTE patients. 
In multivariate hazard models, VTE was associated with arterial thrombotic disease in women 
<65 years (HR 3.28; 95% CI 1.69-6.35), women ≥ 65 years (HR 1.55; 95% CI 1.11-2.18) and 
men <65 years of age (HR 2.06; 95% CI 1.32-3.20), whereas no association was found 
between VTE and future arterial events in men aged >65 years. In conclusion, our findings 
imply that women and men < 65 years with VTE have higher risk of arterial thrombotic 
disease than those without VTE. However, only 1% of the arterial thrombotic events in the 
population were attributed to VTE.  
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4.3 Paper III: Family history of myocardial infarction and cause-specific risk of 
myocardial infarction and venous thromboembolism: the Tromsø Study 
To investigate whether the previously described association between family history of MI and 
VTE14, 149, 194 was mediated by MI, we aimed to determine the risks of MI and VTE by family 
history of MI using a cause-specific model and to explore whether atherosclerotic risk factors 
could explain the associations in a population-based cohort. The study included 21 624 
subjects recruited from the Tromsø Study in 1994-95 and 2001-02. Incident MI and VTE 
events were registered until December 31, 2010. In the cause specific Cox model, person-
years for each participant were counted from the date of enrollment to the date of MI, VTE, 
death or migration or until the end of the study period, whichever came first. There were 1 
311 MIs and 428 VTEs during a median follow-up of 15.8 years. Family history of MI was 
associated with a 52% increased risk of MI (HR 1.52; 95% CI 1.35-1.70) and a 26% increased 
risk of VTE (HR 1.26; 95% CI, 1.02-1.55) in the cause-specific model. Similar results were 
found using a traditional Cox model. The association between family history of MI and VTE 
was confined to unprovoked events and DVT. The highest risk associated with family history 
of MI was found for unprovoked DVT, and family history of MI explained 20.6% of the 
unprovoked DVTs in the population and 82.6% of the unprovoked DVTs in subjects with 
family history of MI. The risk of VTE increased with increasing number of affected relatives, 
and subjects with ≥ 2 relatives with a history of MI had 2.6-fold increased risk of unprovoked 
DVT (HR 2.65; 95% CI 1.12-6.24). Modifiable atherosclerotic risk factors slightly altered the 
association between FHMI and MI but had a negligible effect on the association between 
FHMI and VTE. In conclusion, family history of MI was associated with increased risk of 
both MI and VTE in a cause-specific model. Apparently, the association between FHMI and 
VTE applied to unprovoked DVT and was not explained by modifiable atherosclerotic risk 
factors.  
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4.4 Paper IV: Impact of incident venous thromboembolism on the formation and 
progression of carotid atherosclerosis: the Tromsø Study 
Atherosclerosis secondary to VTE may be an intermediate in the observed association 
between VTE and future arterial CVD.187 We wanted to investigate whether incident VTE 
was associated with subsequent formation and progression of carotid atherosclerosis in a 
population-based observational study. Subjects attending ≥ 2 ultrasound examinations of the 
right carotid artery, with measurements of TPA, in the Tromsø Study in 1994-95, 2002-03 
and/or 2007-08 were eligible for the study. We identified 150 subjects diagnosed with 
incident VTE between the initial and follow-up visit, and randomly selected 600 age- and sex-
matched subjects without VTE between the visits. Subjects with VTE and carotid plaque(s) at 
the first visit had a non-significant 4.1 mm2 (β 4.12, 95% CI -1.72 to 9.98) larger change in 
TPA between the first and second visit compared to subjects without VTE after adjustment 
for change in hs-CRP and traditional atherosclerotic risk factors in the multiple linear 
regression model. The possible association between VTE and plaque progression in subjects 
with carotid plaque(s) remained after restricting the analyses to VTE events diagnosed in the 
first half of the time-interval between the carotid ultrasounds (β 4.02, 95% CI -3.66 to 11.70), 
supporting that the change in TPA occurred subsequent to the VTE. There was no association 
between VTE and TPA at second visit among subjects with carotid plaque(s) in any multiple 
linear regression model, and no association was found between VTE and novel carotid plaque 
formation in logistic regression models. In conclusion, our findings suggest that VTE is 
associated with increased carotid plaque progression in those who already have 
atherosclerosis, but not with novel plaque formation. The possible association between VTE 
and carotid plaque progression was not mediated by low-grade inflammation assessed by hs-
CRP. 
  
   43 
 
5. General discussion 
5.1 Methodological considerations 
5.1.1 Study design  
Observational studies (e.g. cohort and case-control studies) often aim to examine and quantify 
risk factors for health-related outcomes to identify preventable causes. The results in the 
present thesis are based on data from population-based cohort studies. In cohort studies, 
subjects free of a disease of interest are followed over time to investigate the natural history 
and burden of the disease. Moreover, differences in the disease risk according to an exposure 
may be assessed. The cohort design has several advantages including relative and absolute 
risk estimates, the opportunity to examine multiple effects of the same exposure at the same 
time, and a temporal sequence of the exposure and outcome which may yield implications on 
causality.225 In addition, cohort studies may produce generalizable results if a large number of 
subjects from a general population are included. However, a cohort study may encounter 
challenges such as loss to follow-up, change in disease risk during follow-up, bias and 
confounding, inefficiency when examining rare outcomes with long latency periods, and high 
costs.225 Furthermore, the cohort design requires a large study population, which may yield 
problems related to statistical power. Therefore, the low number of VTE events in subgroups 
of our study populations, may represent a potential limitation of the present thesis. Low 
statistical power was a particular issue in paper IV, in which we only had a statistical power 
of 0.29 for the possible association between incident VTE and change in TPA in the 
multivariable model. 
 In case-control studies, subjects with and without the outcome of interest are 
retrospectively compared with regard to an exposure. The case-control has some advantages 
compared with the cohort design, such as the ability to investigate rare diseases with long 
latency periods and cost and time efficiency. Nevertheless, risk estimates from case-control 
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studies are generally considered less valid than those obtained in cohort studies because of 
difficulties related to selection and matching of the controls, the potential for reverse causality 
(i.e. when subclinical presence of the disease influences the exposure226) and recall bias (i.e. a 
bias introduced when subjects with the outcome are more likely to recall information 
regarding the exposure225), and the lack of incidence rates and a temporal sequence of the 
exposure and outcome in a case-control study. 
Positive associations identified in cohort studies are theoretical measures suggesting 
that an exposure may cause the outcome of interest. However, the observed association may 
be non-causal or due to bias, confounding or chance. In contrast, a positive association in an 
experimental study design supports true causality according to Bradford Hill’s criteria for 
causality.227 Moreover, an intervention is needed to investigate the impact of an exposure on 
an outcome in practice. Consequently, randomized controlled trials (RCTs) are recognized as 
the gold standard in modern medicine. In RCTs, the participants are randomly assigned to an 
active or a control group and followed simultaneously to investigate the effect of the 
intervention on the outcome. Elimination of confounding and bias by randomization and 
blinding, respectively, is another advantage of RCTs compared with cohort studies.225 
However, RCTs are expensive, may not provide information on the long-term or rare effects 
of the intervention, and are not always possible to implement due to ethical considerations. 
Furthermore, RCTs most often include younger and healthier subjects than the general 
population due to strict inclusion and exclusion criteria. The risk estimates from RCTs may 
therefore have a lower generalizability than those obtained in population-based cohorts.  
Mendelian randomization is a method for assessing causality within an observational 
study. In this method, the contribution of a modifiable risk factor to disease causation is 
investigated by examining the association between the disease and a genetic variant 
influencing the modifiable risk factor.226, 228 Because alleles are randomly assorted at 
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conception, confounding by other factors than those related to the genetic variant is 
eliminated.226, 228 Furthermore, the fixed genetic makeup at conception excludes the 
possibility of reverse causation.226 Mendelian randomization has previously been applied in a 
prospective cohort study to assess the association between CRP and VTE. In this study, high 
levels of CRP, but not CRP-associated genotypes, were associated with increased risk of 
VTE, suggesting that the observed association between CRP levels and VTE was non-
causal.169 Disadvantages of mendelian randomization include small effect sizes and that the 




The generalizability of a study refers to the study population’s representativeness of its 
defined reference population (i.e. internal validity), and to what extent the results of the study 
may apply to other populations (i.e. external validity).229 The generalizability of a population-
based cohort may be limited by selection bias. The inclusion and exclusion criteria for 
participation, a low response rate, or loss to follow-up (i.e. if subjects lost during the study 
differ from those remaining regarding the risk of the outcome of interest) may introduce 
selection bias.229 Furthermore, a stable disease occurrence during the follow-up (i.e. equal 
disease risk for those entering and leaving the study at different time points) is an important 
assumption for risk assessment. Therefore, follow-up time may influence the validity of a 
cohort study. The median follow-up times in papers I-III were long (12.2-15.8 years). 
However, there were no differences between the comparison groups regarding follow-up time. 
Moreover, the hazard ratios were constant over time when evaluating the parallelism between 
the curves of the log-log survival function and assessing Schonenfeld residuals in the cox 
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proportional hazard model in these papers. This supports that the assumption for risk 
assessment was met in the present thesis. 
The papers in the thesis are based on data from the Tromsø and DCH Studies. To the 
fourth and largest survey of the Tromsø Study, all inhabitants aged 25 years or older living in 
Tromsø were invited, while samples of Tromsø population were invited to the fifth and sixth 
surveys. To the DCH Study, all inhabitants of the urban areas of Copenhagen and Aarhus 
between 50 and 65 years were invited if they were born in Denmark and did not have a cancer 
diagnosis. The attendance rates in Tromsø 4-6 were high, and 66-79% of the eligible 
population participated. However, the attendance rates were somewhat lower in men than in 
women and in subjects below 35 and above 80 years of age in the Tromsø Study, which may 
have reduced generalizability in these subgroups. The generalizability of the DCH Study may 
be limited by a low participation rate and non-response bias because only 35% of the invited 
subjects participated in the DCH Study and those who participated had higher socioeconomic 
status (e.g. higher education, income and occupational status) than the non-participants.216 
Nonetheless, the incidence rate of VTE was only slightly lower in the DCH160 than in the 
Tromsø Study.14 This may be explained by exclusion of subjects aged 65 years or older (i.e. 
those at highest risk of VTE) in the DCH Study. Although participation rates were high, 
nonresponse bias may still be present and reduce the generalizability in the Tromsø Study, 
because subjects with serious illnesses or disabilities tend to refrain from attending health 
examinations. This may result in healthier study participants than the general population, a 
low number of outcome events and underestimation of the true association between the 
exposure and outcome. 
The applicability of the results from one population-based cohort study to other 
populations may also be limited by differences in levels of the exposure, the distribution of 
potential confounders, or the classification of the exposure or outcome in the populations.229 
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In the present thesis, measurement procedures were standardized, only symptomatic VTE 
events were included, and established validation criteria for MI and ischemic stroke were 
applied. Furthermore, our distribution of traditional atherosclerotic risk factors and observed 
incidences of venous and arterial thrombotic diseases did not differ greatly from those 
reported in other Western populations.9, 11, 103, 162, 230-232 This enhances the generalizability of 
our results to other Western populations. 
 
5.1.3 Confounding and interaction 
A confounder is an error in the assessment of the association between an exposure and 
outcome caused by differences between the comparison groups in other risk factors for the 
outcome than the exposure itself.233, 234 In order to confound an association, the confounding 
factor has to be causally associated with the outcome and associated with the exposure. 
Furthermore, the confounder has to be differently distributed among the comparison groups 
and not be an intermediate step in the causal pathway between the exposure and outcome.233, 
234 Confounding may strengthen or weaken a true association. In addition, confounding may 
lead to report of an effect although no true effect exists, or hide a true effect from the results. 
Differences between the comparison groups may produce confounding in cohort studies, 
which are especially vulnerable to unmeasured or unknown confounders.235 In experimental 
studies, randomization minimizes the probability of uneven distribution of known and 
unknown confounders in the comparison groups.235 Confounding is therefore less likely to 
occur in an experimental design. 
High BMI and advancing age were the only traditional atherosclerotic risk factors 
associated with both arterial and venous thrombosis when the risks of MI and VTE were 
investigated in the same population.101, 162 Moreover, family history of MI is a risk factor for 
MI consistently shown to also increase the risk of VTE.14, 149, 194 Consequently, it may be 
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assumed that of the traditional atherosclerotic risk factors, only obesity, increasing age and 
family history of MI may confound the observed interrelation between VTE and arterial CVD 
in the present thesis. Our associations remained statistically significant after adjustments for 
age and obesity in papers I-II and after additionally adjusting for family history of MI in paper 
I. This indicates that these risk factors alone cannot fully explain the observed relation 
between arterial and venous thrombosis. Moreover, inflammation assessed by CRP was a 
potential confounder of the possible link between VTE and carotid atherosclerosis in paper 
IV. High CRP has been shown to increase the risk of both VTE168 and carotid 
atherosclerosis,236 and VTE has been demonstrated to result in elevated CRP levels.237 If, on 
the other hand, the inflammatory state following VTE in turn caused carotid atherosclerosis, 
inflammation would be an intermediate step in the causal pathway between VTE and 
atherosclerosis, and not a confounder. However, there was no association between high CRP 
and carotid atherosclerosis in the Tromsø Study (Agnethe Eltoft, MD, unpublished data, 
2016). In addition, adjustment for hs-CRP did not weaken the possible association between 
VTE and carotid atherosclerosis in subjects with carotid plaque(s) at the first visit in paper IV. 
Taken together, this eliminates inflammation as a confounder or mediator of the possible 
association between VTE and carotid atherosclerosis in the present thesis. 
 Confounding in cohort studies may be minimized by restriction of the study 
participants (e.g. inclusion of men only to eliminate confounding by sex), stratification (i.e. 
division of the study population into subgroups according to the confounding variable) or 
adjustments in regression models.233-235, 238 However, restriction and stratification may reduce 
the statistical power and generalizability. In the present thesis, potential confounders were 
included in the multivariable regression models in order to control for confounding. In paper 
III, cause-specific analyses were additionally performed to investigate the effect of family 
history of MI on the risk of VTE in the complete absence of MI. Furthermore, the risks of MI 
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and VTE were estimated simultaneously in a population with equal distribution of potential 
unrecognized confounders in paper III. Matching of the controls to the cases on potential 
confounders is another strategy to minimize confounding in observational studies.233 
Therefore, the randomly selected subjects without VTE were matched to the VTE patients by 
age and sex in paper IV. 
Although adjustments for potential confounders are made, residual confounding may 
still be present in cohort studies and in the present thesis. The presence of unknown and 
unaccounted for confounders or imperfect adjustments for known confounders (e.g. because 
of imprecise or incomplete assessments) may result in residual confounding.226 FV Leiden 
and prothrombin 20210A are risk factors for VTE found to additionally increase the risk of 
arterial CVD.239, 240 Consequently, residual confounding by thrombophilia on the observed 
link between venous and arterial thrombosis may be present in this thesis. In agreement with 
this, the association between incident VTE and MI diminished after taking genetic 
thrombophilia (i.e. FV Leiden, prothrombin 20210A and non-O blood groups) into account in 
the MEGA Study.188 Furthermore, other yet unknown genetic risk factors for arterial and 
venous thrombosis may be present and cause residual confounding in the present thesis. 
 A statistical interaction is present when the effect of the exposure differs between 
groups of the study population or strata of a second variable (i.e. an effect modifier), and 
results in different risk estimates in subgroups of the population.238 A statistical interaction 
may be positive or negative, and is modelled by stratifying the analyses on the effect modifier 
or by including an interaction term as a covariate in the analyses. In paper II, statistical 
interactions between VTE and sex and VTE and age were identified. Therefore, subsequent 
analyses were stratified on sex and age of 60 years. 
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5.1.4 Information bias 
A bias is a systematic error in a study’s design or procedures, including participant selection 
(i.e. selection bias) and the data collection (i.e. information bias), and may result in incorrect 
assessments of the association between an exposure and outcome.241 Misclassification is a 
type of information bias. Non-differential misclassification of the exposure is present when 
the misclassification is independent of the outcome and similar across the comparison groups, 
while differential exposure misclassification is present when the misclassification is 
dependent of the outcome and differs between the comparison groups.241 Similarly, 
misclassification of the outcome is non-differential if it is unrelated to the exposure, and 
differential if it is dependent of the exposure. A non-differential misclassification most often 
leads to underestimation of the true association, whereas a differential misclassification may 
bias the risk estimates in either direction.241 In prospective cohorts, the exposure is measured 
prior to the disease occurrence. Consequently, potential exposure misclassification is most 
likely non-differential in prospective cohorts. In a case-control study, recall bias and 
differential exposure misclassification may be present because information regarding the 
exposure is collected after the outcome occurrence.241 
Most baseline variables from the Tromsø and DCH Studies are based on self-
administered questionnaires. Although self-administered questionnaires have several 
advantages, including cost and time efficiency, they introduce a potential source of 
misclassification if the study participants provide false information (e.g. misunderstand or 
refrain from answering questions). This is of particular importance in paper III, in which the 
exposure was self-reported family history of MI. Among those who reported family history of 
MI, both over- and under-reporting are possible. However, the potential misclassification of 
family history of MI was most likely non-differential because information regarding family 
history of MI was collected prior to the MI and VTE diagnoses. This may have caused 
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underestimation of the true associations between family history of MI and MI and VTE in our 
study. Underestimation of the true associations is further supported by a high specificity and a 
lower sensitivity of self-reported family history of MI previously demonstrated in a validation 
study.242 The validity of the information from a self-administered questionnaire may be 
assessed by investigating the effect of the question of interest on other factors than the 
outcome. Family history of MI increased the risk of MI in addition to VTE in paper III, as 
expected from previous publications.189-191 This supports the validity of the self-reported 
family history of MI in the assessment of the association between family history of MI and 
VTE in this thesis. 
Blood samples and ultrasound assessment of carotid atherosclerosis were also 
potential sources of information bias in the present thesis. However, standardized procedures 
for measurements of blood samples and carotid ultrasound were used in the Tromsø Study to 
reduce bias. Carotid ultrasound was performed by personnel who had completed a pre-study 
training protocol to ensure equal and standardized examination techniques and measurements, 
and all sonographers followed identical procedures and used identical ultrasound scanners. In 
addition, a previous publications from the Tromsø Study has demonstrated that although 
carotid plaque thickness measurements were subject to considerable measurement errors, the 
between- and within-sonographer agreement for carotid plaque occurrence was substantial.223 
Furthermore excellent computer-assisted offline classification for carotid plaques has been 
found in the Tromsø Study, even if the outlining of plaques was influenced by measurement 
errors.243 Hs-CRP was measured from frozen blood samples stored for 12 years in Tromsø 4, 
which may have introduced bias if the freezing or storage affected the hs-CRP measurements. 
However, storage of frozen plasma samples over time has previously been shown to not affect 
the assayed values of biomarkers including CRP.244 
 
   52 
 
5.1.5 Modifiable risk factors and time-scale 
Modifiable risk factors are a possible limitation of prospective cohort studies, particularly 
when the exposure is collected at baseline only and the time between the exposure and 
outcome is long. Modifiable risk factors imply that the risk profile of the study participants 
may change during follow-up. It may result in regression dilution bias (i.e. underestimation of 
the true association between the exposure and outcome because information regarding the 
exposure is collected at baseline only and not updated during follow-up).241, 245 In agreement 
with this, results from the Framingham and Whitehall Studies have shown that investigation 
of the association between the baseline measurement and disease risk underestimated the 
strength of the real association by 30% during the first decade of follow-up, and that change 
in risk profile became progressively more important with increasing follow-up time.245 
In papers I and II, the exposure variables (i.e. MI and VTE, respectively) were 
included as time-dependent covariates and continuously updated during follow-up, thereby 
limiting the risk of regression dilution bias. However, most other covariates of interest, such 
as blood pressure, blood lipids, BMI and smoking, were modifiable and only collected at 
baseline in paper II. In order to further reduce the potential for regression dilution bias, time-
varying analyses in which covariates of interest are updated during follow-up may be 
performed. In paper I, information regarding the covariates was updated at each survey for 
subjects who attended more than one survey. 
 In the Cox proportional hazard model, the variable expected to have the largest effect 
on the hazard (e.g. time-on study or age) should be used as the time-scale.246 The hazard of a 
disease is expected to change more as a function of age than as a function of time-on study 
because the incidence of most chronic diseases is strongly determined by age, whereas study 
inclusion rarely affects disease risk.247 Therefore, age was used as time-scale in papers I and 
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II. Furthermore, the use of age as time-scale is a more effective method to control for age than 
the use of time-on study as time-scale and adjusting for age at baseline.247 
 
5.1.6 Missing values 
Missing values are a common problem in epidemiologic research and may cause bias.248-250 
Missing values may result from subjects not responding to questions in the questionnaire, loss 
to follow-up, equipment failure or procedural mistakes, or unknown reasons.248, 251 A few 
missing values are of minor importance, whereas a large amount of missing values in a 
variable may threaten the integrity of the study.248 Although no optimal solution for missing 
values exists, missing data may be handled by deletion of variables with a substantial amount 
of missing values, deletion of subjects without a complete dataset (i.e. complete case analysis 
or listwise deletion), exclusion of subjects with missing values for the variables of interest in 
the statistical analyses (i.e available case analysis or parwise deletion), or imputation (i.e. 
calculating an estimate for each missing value and replacing it).248-251  
Deletions may introduce selection bias if the characteristics of those with missing 
values differ from the rest of the study population and may result in reduced statistical 
power.248, 249, 251 In contrast, imputation ensures the sample size and reduces the risk of 
selection bias.249 Imputation is based on the assumption that the missing values are missing at 
random (i.e. the lack of the observation is unrelated to the unobserved value but is explained 
by other available observations in the dataset) or missing at completely random (i.e. the lack 
of the observation is unrelated to the unobserved value and other available observations in the 
dataset).248, 250, 251 In the present thesis, missing data were handled by excluding subjects with 
missing data on the exposure or outcome variable of interest (i.e. complete case analysis), and 
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by omitting subjects with missing values for covariates in the statistical analyses (i.e. 
available case analysis). 
Missing values were a particular issue in paper III, in which 5 038 subjects (17.6%) 
had missing values for the exposure variable family history of MI. Most likely, the majority of 
subjects with missing information on family history of MI refrained from answering the 
question because they did not have relatives with a history of MI. Consequently, the missing 
values for family history of MI were most likely not missing at random, and imputation was 
not performed. A potential bias caused by missing values in a binary variable may be 
addressed by sensitivity analyses (i.e. examining the effect of replacing the missing values 
with the extreme scenarios of the variable).250 When we performed analyses under the 
assumption that (i) all subjects with missing values did not have a family history of MI, and 
(ii) that all subjects with missing values had family history of MI, the risk estimates for MI 
and VTE did not change notably. This supports our use of complete case analysis in paper III. 
 
5.1.7 Registration of incident VTE, MI and ischemic stroke 
In the Tromsø Study, all first-time in- and outpatient VTE events during follow-up were 
retrospectively identified by searching registries at UNN. Because UNN is the only hospital in 
the Tromsø region, the probability of a complete VTE registry is high. However, some study 
participants may have been diagnosed with VTE elsewhere and may therefore have been 
missed. Nevertheless, several of the VTE events diagnosed elsewhere were discovered due to 
transferal to follow-up at the outpatient clinic at UNN.  
 Trained personnel reviewed the medical record for each potential VTE case. The VTE 
events were verified and recorded according to strict criteria as previously described in the 
thesis to reduce the likelihood of inclusion of asymptomatic events and misclassification. 
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However, potential outcome misclassification cannot be completely ruled out. The 
retrospective registration of the VTE events was dependent on accurate and complete 
information provided in the medical records by the individual medical doctors diagnosing and 
treating the VTE patients, and there was no standardized instruction for the recording of VTE 
events in the medical records. Furthermore, assessment of provoking factors relied on 
information provided for each patient. Nonetheless, the potential misclassification present in 
the VTE variable is most likely non-differential because the endpoint committee validating 
the VTE events were blinded to baseline characteristics of the potential VTE patients. Finally, 
information regarding previous VTE was not available for study participants who were not 
diagnosed with VTE during follow-up. This may imply that subjects with prevalent VTE are 
included as healthy subjects and not excluded in the present thesis. However, the proportion 
of subjects with prevalent VTE is most likely small, and a minor effect on our risk estimates 
can therefore be expected. 
All first-time MI and ischemic stroke events during follow-up were identified 
retrospectively in the Tromsø Study by searching medical records, autopsy records and death 
certificates, and by linkage to national and local diagnosis registries and to the National 
Causes of Death Registry at Statistics Norway. The National Causes of Death Registry covers 
all subjects registered as inhabitants of Norway at the time of their death, without regard to 
whether the death took place in Norway or abroad, in order to ensure a complete follow-up 
status for all-cause mortality. An independent endpoint committee reviewed the medical 
record for each potential MI and ischemic stroke case, and MI and ischemic stroke events 
were verified and recorded according to a strict classification protocol to warrant accurate 
outcome variables as previously described in the thesis. Some MI and ischemic stroke events 
may have been diagnosed and treated in other hospitals than UNN. However, the number of 
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MI events observed at other hospitals and the location of the hospitals was available for the 
retrieved MI cases. 
The identification and validation of VTE, MI and ischemic stroke in the DCH study 
was performed in a similar matter. 
 
5.2 Discussion of main results 
5.2.1 Myocardial infarction and the risk of venous thromboembolism 
In accordance with previous studies,174, 176, 177 we found that MI was associated with increased 
risk of subsequent VTE. The observed association between MI and future VTE applied to PE. 
In accordance with this, Sørensen et al demonstrated higher risk of PE than DVT after 
hospitalization for MI when subjects with a history of MI were compared with population-
based controls.176, 177 Similar risk estimates for unprovoked and provoked VTE were found 
after MI in these Danish registry-based studies.176, 177 In our study, MI was only associated 
with subsequent provoked VTE. However, the results of Sørensen and coworkers should be 
interpreted with caution because the exposure, outcome, potential confounders and provoking 
factors for VTE were based on information from hospital registries and the Danish National 
Patient Registry only and not validated.176, 177 According to our results, the risk of VTE was 
highest during the initial 6 months following the incident MI event, and then rapidly declined 
and was no longer significantly increased. Similarly, a particularly high risk of VTE was 
found the first 3 months after a MI diagnosis in postmenopausal women,114 and the 
association between MI and VTE has been reported to diminish177 or disappear176 beyond 3 
months after MI hospitalization. This indicates that MI patients are at short-term increased 
risk of VTE. 
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 Our study is the first to investigate the attributable risk and the population attributable 
risk of incident PE due to incident MI. We found that 6% of the PE events in the population 
were attributed to MI and that nearly 80% of the PE events among MI patients were explained 
by the MI. The considerable number of PE events attributable to MI and the transient nature 
of the VTE risk after MI may suggest a role for anticoagulant therapy in MI patients with high 
risk of VTE to prevent subsequent PE. Aspirin252, 253 and statins254 have previously been 
shown to reduce the risk of recurrent and incident VTE, respectively. Consequently, 
concomitant treatment with aspirin and statins following the MI diagnosis may have resulted 
in underestimation of the true impact of MI on the risk of future VTE. 
 The underlying mechanisms explaining the observed association between MI and 
future VTE remain unsettled. Potential mechanisms include common risk factors, indirect 
factors, and a direct causal interrelation.255 Adjustment for common risk factors for MI and 
VTE, such as age, obesity and family history of MI, in addition to other traditional 
atherosclerotic risk factors had marginal effects on our risk estimates. Furthermore, common 
risk factors for MI and VTE would mediate a permanent and not a transient increase in the 
risk of VTE. Consequently, our findings argue against a strong impact of shared risk factors 
alone on the association between MI and subsequent VTE. However, residual confounding by 
other shared risk factors may still be present and partially mediate the observed association 
between MI and future VTE. In addition, synergistic effects of several shared risk factors or a 
combination of shared risk factors and MI sequela may result in venous thrombus formation 
in MI patients. 
 The transient increase in VTE risk after MI we and others have reported114, 176, 177 
points towards causal mechanisms related to the MI itself or indirect factors such as 
hospitalization, immobilization or other conditions following the MI. Accordingly, decreased 
left ventricular ejection fraction is a potential complication of MI shown to increase the risk of 
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future VTE.256 Moreover, a higher frequency of immobilization and VTE occurrence during 
hospitalization has been found in VTE patients with symptomatic atherosclerotic disease than 
in those without.257 An impact of hospitalization on the association between MI and future 
VTE is further supported by higher risk estimates for VTE demonstrated when VTE was the 
second diagnosis in the medical records and lower risk estimates shown when the VTE did 
not occur during the hospitalization for heart disease by Sørensen et al.177 This may imply that 
MI hospitalization rather than the MI itself is a risk factor for VTE, and that MI is indirectly 
associated with VTE through MI hospitalization. In agreement with this, the strength of the 
association between MI and VTE found by Barsoum and coworkers was markedly attenuated 
after adjustment for hospitalization for major surgery or acute medical illnesses.178 The 
particularly high PE risk and the transient nature of the VTE risk after MI may also imply that 
direct causal mechanisms secondary to local disturbances in the cardiopulmonary circulation 
or the electromechanical activity are responsible for some of the increase in VTE risk 
observed in MI patients. Accordingly, AF is a potential MI sequelae previously found to be 
associated with a particularly high risk of PE in the Tromsø Study.61 
 
5.2.2 Venous thromboembolism and the risk of myocardial infarction and ischemic stroke 
In the present study (paper II), we found that incident VTE was associated with increased risk 
of future MI and ischemic stroke. Our findings are in accordance with previous 
publications180-184, 186-188 and have later been confirmed in a trial of subjects with impaired 
glucose tolerance and established CVD reporting that VTE patients had more than two times 
higher risk of death, MI and stroke combined than those without VTE after adjustments 
including obesity.258 Moreover, an association between DVT and future arterial events has 
recently been reported.259 In contrast, Barsoum and coworkers failed to find an association 
between incident VTE and MI.178 However, this study was limited by a lack of power to 
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detect a significant association between venous and arterial thrombosis of the magnitude we 
found, and excluded VTE patients who did not survive at least one day after the VTE event.178 
According to our findings, the incidence of arterial CVD was highest the first year after a PE 
event. Similarly, Sørensen et al reported particularly high risk of arterial thrombotic diseases 
the first year after a PE, in which PE patients had nearly 3-fold increased risk of MI and 
stroke.187 Furthermore, the highest risk of arterial events in VTE patients was found the initial 
year after the VTE diagnosis in the Prevention of Renal and Vascular Endstage Disease 
(PREVEND) Study.186  
Our crude incidence rates of arterial thrombotic diseases after VTE were lower than 
those previously reported in cohort studies.180-182, 184 Differences in methodology and 
particularly selection of the study population may explain these differences in incidence rates. 
We followed all VTE patients from the initial stage of the disease, including the VTE patients 
who died shortly after the VTE diagnosis and were no longer at risk of arterial thrombotic 
diseases. In contrast, other studies only included VTE patients who had completed oral 
anticoagulant treatment180 or survived the initial month after the VTE event.182 Moreover, 
VTE patients with an indication for long-term anticoagulation have previously been 
excluded.182, 184 Anticoagulant therapy has been shown to reduce the risk of MI and 
cerebrovascular events.260, 261 Long-term anticoagulant therapy may therefore partly explain 
the lower incidence rates found in our study. Finally, cancer is a known risk factor for arterial 
thrombotic diseases,134 and exclusion of all subjects with a previous cancer diagnosis at 
baseline from the DCH Study may consequently have contributed to the observed differences 
in incidence rates of arterial CVD after VTE. 
We found that the association between incident VTE and future arterial CVD applied 
to all women and men below 65 years of age. An interaction between VTE and sex on the risk 
of arterial thrombosis has not previously been described. However, Sørensen et al reported 
   60 
 
slightly higher risk estimates of arterial CVD in women compared with men the initial year 
after a PE diagnosis.187 Although our findings should be interpreted with caution because of 
limited statistical power in subgroup analyses, the sex difference in arterial CVD risk after 
VTE may suggest a differential pathogenesis of arterial thrombotic disease in men and 
women. This is further supported by the observed difference in arterial CVD risk according to 
VTE type in men and women. We demonstrated that PE rather than DVT increased the risk of 
arterial events in men, whereas PE and DVT provided similar risk estimates of arterial CVD 
in women. Sørensen and coworkers found lower risk of arterial CVD after DVT compared 
with PE,187 whereas similar risk estimates were obtained for arterial thrombotic events 
following DVT and PE in the MEGA and PREVEND Studies.186, 188 However, differences in 
the risk of arterial CVD according to VTE type were not assessed in men and women in these 
studies. An impact of age on the association between venous and arterial thrombotic diseases 
has previously been demonstrated. The association between incident unprovoked VTE and MI 
has been shown to only apply to subjects below 40 years of age,183 and higher risk of 
subsequent arterial events has been demonstrated in PE patients aged 40-55 years compared 
with PE patients above 70 years of age.187 
Our study is the first to explore the proportion of arterial thrombotic events 
attributable to incident VTE. Although the population attributable risk of arterial CVD due to 
VTE was low (1%), a considerable proportion of the arterial events in VTE patients were 
attributable to incident VTE (64%). Our findings could imply a role for arterial CVD 
prophylaxis in VTE patients with high risk of arterial events to prevent subsequent arterial 
CVD. Concomitant anticoagulation and antiplatelet therapy may increase the risk of bleeding, 
and prediction models to identify the VTE patients at high risk of arterial CVD who may 
benefit from arterial CVD prophylaxis are therefore needed. However, most of the presently 
known predictors of subsequent arterial events in VTE patients receiving anticoagulant 
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treatment (e.g. cancer and anemia) were also predictors of major bleeding.262 Hopefully, 
future studies will identify accurate and sensitive predictors of arterial events following VTE 
and investigate the effects of arterial CVD prophylaxis on the risk of future MI and ischemic 
stroke in high-risk VTE patients. 
Common risk factors such as advancing age and obesity may potentially explain an 
association between VTE and future arterial CVD.101, 162 However, adjustment for age and 
BMI in addition to other traditional atherosclerotic risk factors only slightly attenuated the 
observed interrelation between venous and arterial thrombosis in our and the MEGA Study,188 
thereby challenging that these common risk factors alone can fully explain the association. 
Nevertheless, Roach et al showed that the association between incident VTE and MI 
disappeared after additionally taking FV Leiden, prothrombin 20210A and non-O blood 
groups and fibrinogen, FVIII and CRP into consideration.188 Furthermore, an initially 
observed association between DVT and future arterial events diminished after adjustment for 
atherosclerotic risk factors and cancer in a recent publication.259 This supports that common 
etiologic factors may explain an association between VTE and future arterial CVD. It is also 
possible that the observed increase in arterial CVD risk in VTE patients is explained by the 
VTE events themselves or treatment thereof, such as local disturbances in the 
cardiopulmonary circulation following a PE, paradoxical embolization of a venous thrombus 
through a patent foramen ovale,263-265 or vascular calcification caused by VKA therapy.266 
 
5.2.3 Family history of myocardial infarction and the risk of myocardial infarction and 
venous thromboembolism 
We found that family history of MI was associated with increased risk of both MI and VTE, 
thereby confirming the results of previous publications.14, 149, 189-194 However, our risk 
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estimates for MI were lower than those previously reported.189-193 This may be explained by 
differences in study design and selection of study participants. We recruited subjects from a 
general population prior to MI occurrence and followed them prospectively for all MI events. 
In contrast, other studies were retrospective,189-193 and only included non-fatal MI cases,189, 191 
hospitalized controls189, 190, 192 or registered relatives of MI patients as controls.193 In 
agreement with our finding, a history of MI before 60 years of age in a first degree relative 
has previously been shown to increase the risk of incident VTE by approximately 30% after 
adjustment for other traditional atherosclerotic risk factors.14, 149 
The proportion of incident VTE events attributable to family history of MI was 13% in 
our study population, compared to 11% in the GATE Study.194 According to our finding, the 
proportion of VTE events in the population attributable to family history of MI was 
comparable with the proportion of VTE events attributable to family history of VTE.267 This 
may implicate a role for family history of MI in clinical practice to improve the identification 
of subjects at high risk of VTE. 
In agreement with existing literature,14, 189, 190, 194 we found that the risk of both MI and 
VTE increased with increasing number of affected first degree relatives with a history of MI. 
Moreover, the observed association between family history of MI and VTE applied to 
unprovoked events, and particularly unprovoked DVT, confirming previous results from the 
Tromsø and HUNT Study.14, 149 Taken together, our findings may suggest that shared genetic 
risk factors for MI and VTE such as factor V Leiden239, 240 contribute to the observed 
association between family history of MI and VTE. Factor V Leiden has been identified as a 
stronger risk factor for DVT than PE.69, 89, 90, 97 This may explain the particularly high risk of 
unprovoked DVT found in subjects with a family history of MI. 
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We confirmed that modifiable atherosclerotic risk factors such age, blood pressure, 
cholesterol and BMI influenced the association between family history of MI and MI. In 
addition, family history of MI had a synergistic effect with age, BMI and cholesterol on the 
risk of MI. In agreement with our findings, dyslipidemia has previously been shown to have a 
multiplicative effect with family history of MI on the risk of MI.190-192 Moreover, family 
history of MI has been reported to have synergistic effects with diabetes mellitus and 
fibrinogen on the risk of VTE.194 In contrast, we found no interactions between family history 
of MI and other traditional atherosclerotic risk factors. Furthermore, modifiable 
atherosclerotic risk factors had a negligible effect on the observed association between family 
history of MI and incident VTE. This indicates that the observed association between family 
history of MI and VTE was not explained by traditional atherosclerotic risk factors. Finally, 
our risk estimates for VTE by family history of MI were similar in the traditional and the 
cause-specific Cox model. Consequently, the observed association between family history of 
MI and VTE was not explained by an indirect relation between MI and VTE previously 
described in this thesis. 
  
5.2.4 Venous thromboembolism and the risk of carotid atherosclerosis 
In the present study (paper IV), a possible association between incident VTE and plaque 
progression was found in subjects who already had carotid plaque(s). An association between 
carotid plaques and VTE has previously been described in case-control studies reporting 
significantly higher prevalence of carotid plaques in unprovoked DVT patients than controls 
without VTE.208, 210 However, these studies only included DVT patients and were not 
designed to explore the temporal sequence between VTE and subsequent atherosclerosis.208, 
210 Our study is the first designed to model the time-sequence between incident VTE and 
carotid atherosclerosis. Although our findings must be interpreted with caution due to limited 
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statistical power, the possible association between VTE and carotid plaque progression found 
among those with established atherosclerosis remained after restricting the analyses to VTE 
events diagnosed in the first half of the time-interval between the carotid ultrasounds. This 
supports that the change in TPA in subjects with carotid plaque(s) occurred subsequent to the 
VTE. However, incident VTE was not associated with subsequent formation of new carotid 
plaques. To the best of our knowledge, the interrelation between incident VTE and future 
carotid plaque formation or progression has not previously been investigated in a general 
population. 
 Elevated levels of inflammatory markers including CRP have previously been 
demonstrated in both the acute268, 269 and chronic237, 270 phase of VTE, and CRP levels have 
been shown to remain significantly higher five years after a VTE diagnosis compared with 
subjects without VTE.237 Furthermore, CRP has been found to independently increase the risk 
of arterial CVD,271-273 and a nearly linear relationship between CRP concentrations and 
arterial CVD risk has been described.274 This suggests that chronic low-grade inflammation 
accompanying VTE may contribute to the increased risk of arterial CVD observed in VTE 
patients.187 Inflammation may also be related to atherosclerosis, and high levels of CRP have 
been found to independently increase the risk of presence236, 275-280 and progression236, 278-280 of 
atherosclerosis. Levels of hs-CRP were independently associated with carotid IMT in a 
prospective cohort276 and meta-analysis,277 and increasing severity of extracranial 
atherosclerosis with increasing CRP levels has been described.278 Moreover, CRP levels >2.9 
mg/L have been shown to nearly double the odds of carotid atherosclerosis progression 
compared with CRP levels ≤0.8 mg/L.279 Taken together, this could imply that the possible 
association between incident VTE and acceleration of plaque progression we have shown in 
subjects with carotid plaque(s) was mediated by low-grade inflammation. 
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 However, other studies have failed to find an independent association between CRP 
and carotid plaques,281, 282 and demonstrated that although hs-CRP predicted atherosclerosis 
presence, it was not sensitive to monitor progression of atherosclerosis.276, 277 Moreover, it has 
recently been shown that high hs-CRP levels were not associated with progression of carotid 
atherosclerosis after taking traditional atherosclerotic risk factors into account in the Tromsø 
Study (Agnethe Eltoft, MD, unpublished data, 2016), and the possible association between 
VTE and carotid plaque progression we found in subjects with carotid plaque(s) remained 
unchanged after adjusting for hs-CRP. Finally, we showed that the apparent association 
between VTE and carotid plaque progression among those who already had atherosclerotic 
plaques was strengthened when traditional atherosclerotic risk factors, and specifically 
smoking and BMI, were taken into consideration. Similarly, Jezovnik and coworkers found 
higher risk estimates for atherosclerotic plaques in DVT patients after adjusting for 
atherosclerotic risk factors.210 Taken together, this may imply that the possible association 
between incident VTE and atherosclerosis progression in those with already established 
carotid plaque(s) is independent of traditional atherosclerotic risk factors and low-grade 
inflammation accompanying the VTE.  
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6. Conclusions 
A: We found that incident MI was associated with increased risk of future VTE, and 
particularly of PE, after adjusting for potential confounders, and that 6% of the VTE events in 
the population could be attributed to MI. The VTE risk after MI was transient, which suggests 
that direct or indirect causal mechanisms related to the MI event itself are primarily 
responsible for the observed association. 
B: In our study, we found that all women and men <65 years of age with incident VTE had 
increased risk of future MI and ischemic stroke after adjusting for potential confounders, such 
as BMI. However, only 1% of the arterial thrombotic events in the population were attributed 
to VTE. 
 C: In our study, incidence rates of MI and VTE according to family history of MI were 7 and 
2 per 1000 person-years, respectively, and family history of MI increased the risk of both 
incident MI and VTE. Apparently, the association between family history of MI and VTE 
applied to unprovoked DVT, and the risk of unprovoked DVT increased with increasing 
number of affected first-degree relatives with a history of MI. 
D: The associations between family history of MI and incident MI and VTE were similar in 
the cause-specific and the traditional Cox model, and modifiable atherosclerotic risk factors 
did not explain the association between family history of MI and VTE. 
E: We found that incident VTE was associated with atherosclerosis progression in those with 
already established carotid plaques, but not with novel plaque formation. The possible 
association between VTE and carotid plaque progression was not mediated by low-grade 
inflammation assessed by hs-CRP.   
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7. Final remarks and future perspectives 
Based on the existing literature and the findings in this thesis, there appears to be a 
bidirectional association between incident VTE and arterial CVD. MI explained 6% of the 
PEs in our study population and the attributable risk of PE due to MI was high. Development 
of a VTE risk prediction model to recognize high risk MI patients in need of VTE prophylaxis 
is therefore pivotal, and future studies are needed to identify predictors of VTE following MI 
and assess whether implementation of a VTE risk prediction model in MI patients may reduce 
the incidence of VTE. The transient increased risk of VTE following MI may imply a role for 
prolonged anticoagulant therapy in high-risk MI patients to prevent subsequent VTE. 
Moreover, results of RCTs indicate that short-term VKA therapy is more effective than 
aspirin in reducing the risk of future arterial CVD in MI patients.260, 261 However, the effect of 
prolonged anticoagulation and the effect of VKA on future VTE risk was not investigated, 
and further studies are warranted. 
 Similar inferences may be drawn from the observed association between VTE and 
future arterial CVD. However, the number of arterial events attributed to VTE in our study 
population was low. Implementation of a prediction model to recognize high risk VTE 
patients in need of arterial CVD prophylaxis is therefore unlikely to influence the incidence of 
arterial CVD greatly. Finally, aspirin to prevent arterial events in VTE patients is 
controversial because of the lower potency of aspirin compared with anticoagulant therapy in 
preventing arterial events found in MI patients.260, 261 Statin treatment has been shown to 
decrease the risk of incident VTE.254 From this it may be hypothesized that statins in VTE 
patients at high risk of arterial events may reduce the risk of both recurrent VTE and 
subsequent arterial CVD. However, statins as a supplement to anticoagulant therapy in VTE 
patients has to the best of our knowledge not previously been explored and further studies are 
needed.  
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